Morphocell Technologies’ mission to transform the treatment of liver disease is rooted in the excellence of our science and the people who drive it forward.

 

On that note, we are thrilled to announce that Dr. Jennifer Moody will join us as Chief Operating Officer beginning October 7th, 2019. Jennifer is a stem cell commercialization and business operations expert with deep experience in the Canadian and global ecosystems, who most recently served as Senior Director of Research Operations at BlueRock Therapeutics in Toronto.

 

She brings to the team 23 years of experience in stem cell science, 13 of those years in industry commercializing products spanning from stem cell reagents to cell-based therapeutics.

 

“We are incredibly fortunate to add Dr. Moody to our team as we ramp up toward first-in-human clinical trials for ReLiver®ELT,” said Dr. Massimiliano Paganelli, pediatric transplant hepatologist at Sainte-Justine University Hospital Center in Montreal and co-founder of Morphocell. “She brings a whole new level of expertise and savviness to our R&D, clinical trial and commercialization programs and will be a tremendous collaborator going forward.”

 

“It has been several years since I first met the Morphocell team and I have enthusiastically followed their progress.” said Dr. Moody. “The vision and drive of the founding team has significantly advanced and de-risked their technologies. I am excited to be joining the team and look forward to contributing to the development of Morphocell’s proprietary engineered liver tissue to create a cell therapy product to address the significant unmet medical need that currently exists for liver disease.”

 

Bio: Dr. Jennifer Moody, PhD

​

Dr. Jennifer Moody obtained a BSc in genetics from York University (Toronto), a PhD in Genetics from UBC (Vancouver), and pursued postdoctoral studies at the Lund Stem Cell Centre in Lund, Sweden. From there she joined STEMCELL Technologies in Vancouver as an R&D scientist, where she led commercial development of the TeSR product line. This was followed by almost six years at the Centre for the Commercialization of Regenerative Medicine (CCRM) in Toronto immersed in operations, alliance management and business development responsibilities. Jennifer joined BlueRock Therapeutics shortly after its formation, staying through to the recent acquisition by Bayer Pharmaceuticals and was instrumental in establishing the company’s pluripotent stem cell platform that will enable its future clinical programs. Jennifer is a member of ISSCR and ISCT, serves on the ISCT Business Model and Investment subcommittee and is a member of the Rotman Business School Healthcare and Life Sciences Leadership Network. Most recently she was selected as a participant in the 2019-2020, Pfizer-sponsored AdMare Executive Institute, a leadership development program for Canadian life science talent.